SOUMYAJIT ROY(@SouMyajiT_RO) 's Twitter Profileg
SOUMYAJIT ROY

@SouMyajiT_RO

Human Physician #RadOnc #Researcher proud #IMG @RushCancer resident. Editor @ASTRO_org @FrontOncology MSc Biostat+Epidem @EdinburghUni #RStats #PCSM enthusiast

ID:4873918177

calendar_today07-02-2016 13:47:30

982 Tweets

499 Followers

399 Following

Dr. Vijay Patil(@DrVijayPatil11) 's Twitter Profile Photo

Low-Dose Immunotherapy has made immunotherapy more accessible, and has brought down the cost of therapy from 60-80 lakhs to below 5.0 lakhs per year. Hugh cost saving. A step towards atmanirbhar Bharat. PMO India TOI India NDTV Zee News The Hindu ascopubs.org/doi/abs/10.120…

account_circle
SOUMYAJIT ROY(@SouMyajiT_RO) 's Twitter Profile Photo

Completely agree with this. A comprehensive health equity committee should have representation from all sides. It is pivotal to realize the ground reality before implementing policies. Else everything will be futile.

account_circle
AIIMS, New Delhi(@aiims_newdelhi) 's Twitter Profile Photo

Patients visiting AIIMS, New Delhi for various ailments are seen at AIIMS 24x7 without any registration charges. All investigations charged less than 300 INR have been exempted so that Health care is

account_circle
SOUMYAJIT ROY(@SouMyajiT_RO) 's Twitter Profile Photo

This is really encouraging. Congratulations May F. Elbanna. I am sure you will do wonders. Thank you very much ASTRO ARRO. Looking forward to see how are integrated under the umbrella of . IMG Oncologists

account_circle
SOUMYAJIT ROY(@SouMyajiT_RO) 's Twitter Profile Photo

Terribly frustrated with this publication politics - 'Your article is not suitable for my journal but for a sister journal which will reach wider audience as it is open access and it would need you to sell your kidney to pay the article submission fees.' Stop this crap.

account_circle
Bobby Koneru, MD(@KoneruMd) 's Twitter Profile Photo

How do we protect from losing like LU-177 to nuclear medicine, urology or medical oncology? I feel like this is an important domain loss that our specialty isn’t taking seriously enough.

account_circle
Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo

Latest paper from Dr. Andy Wang 🇺🇦 UTSW Radiation Oncology UTSW Simmons Cancer Center on engineered metastases as cancer vaccine with higher immune responsiveness to cancer immunotherapy. Dr. Sultanpuram is one to watch - interviewing for radiation oncology residency this season!

Latest paper from @andyzwang #NikhilaSultanpuram @UTSW_RadOnc @utswcancer on engineered metastases as cancer vaccine with higher immune responsiveness to cancer immunotherapy. Dr. Sultanpuram is one to watch - interviewing for radiation oncology residency this season!
account_circle
Neeraj Agarwal(@neerajaiims) 's Twitter Profile Photo

Breaking news: Phase 3 randomized TALAPRO-2 trial of Enza + Talazoparib vs. Enza meets primary endpoint in the 1st line mCRPC in both HRR+ and HRR- patients (study design👇).Press release 👉 bit.ly/3SSjJAp OncoAlert UroToday.com GU Cancer Research Program @HuntsmanCancer PCF Science

Breaking news: Phase 3 randomized TALAPRO-2 trial of Enza + Talazoparib vs. Enza meets primary endpoint in the 1st line mCRPC #ProstateCancer in both HRR+ and HRR- patients (study design👇).Press release 👉 bit.ly/3SSjJAp @OncoAlert @urotoday @Huntsman_GU @PCF_Science
account_circle
Danny Vesprini(@dr_vesi) 's Twitter Profile Photo

The ASCENDE-SBRT trial. HDR brachy+23# EBRT vs. 5# SBRT for unfavourable prostate ca. Amazing CCTG study led by Dr. Andrew Loblaw Sunnybrook Health Sciences Centre.
Can non-invasive, cheaper high precision SBRT be used to avoid invasive brachy + GA & multiple visits ?
Shift that paradigm!

The ASCENDE-SBRT trial. HDR brachy+23# EBRT vs. 5# SBRT for unfavourable prostate ca. Amazing @CDNCancerTrials study led by @DrAndrewLoblaw @Sunnybrook. Can non-invasive, cheaper high precision SBRT be used to avoid invasive brachy + GA & multiple visits ? Shift that paradigm!
account_circle
Ariela Marshall MD(@AMarshallMD) 's Twitter Profile Photo

International medical graduates face many barriers - is unfortunately one
Our research 👇🏽 - let's use this to improve things for our trainees!
ASCO ASH Penn Cancer Innovation

ascopubs.org/doi/full/10.12…

account_circle